title: When does superficial bladder cancer resist intravesical therapy?
authors.affiliation: Department of Urology, University of Düsseldorf, Federal Republic of Germany.
authors.forename: T
authors.initials: T
authors.lastname: Vögeli
authors.forename: R
authors.initials: R
authors.lastname: Ackermann
mesh_terms: D000283:Administration, Intravesical; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000627:therapeutic use; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology; D014516:Ureteral Neoplasms / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine